Delay after delay…When will Phesgo be reimb in Korea?
By Eo, Yun-Ho | translator Kang, Shin-Kook
24.05.31 05:45:56
가나다라
0
Pending for 10 months after passing CDDC review last August
Government and pharmaceutical companies’ willingness is key...Industry attention on whether the drug will be reimbursed or not
Roche Korea’s subcutaneous fixed-dose combination injection Phesgo (pertuzumab, trastuzumab) that combined ‘Perjeta’ and ‘Herceptin’ has passed the Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee review in August last year.
After reporting to the Drug Reimbursement Evaluation Committee review, Roche started negotiations with the National Health Insurance Service regarding the supply and quality control obligations for Phesgo but had made no progress. The 60-day deadline for negotiations has already passed, and no agreement has been reached i
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)